Michael Scholle Appointed CEO of Tango Biosciences, the premier research partner for custom affinity reagents by phage ...

As humans, we often focus on viruses and bacteria because of their role in causing various, sometimes severe, diseases.

Researchers from the Technion uncover a novel passive resistance mechanism in marine bacteria. By reducing tRNA levels, ...

The human gut microbiome is complex and diverse, with significant implications for health and disease. The study develops ...

PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces an update on its ...

The Bangladesh Society of Microbiologists (BSM) recently observed World AMR (Antimicrobial Resistance) Awareness Week (WAAW) ...

Researchers developed AbMAP, a cutting-edge framework leveraging transfer learning to model antibody hypervariable regions, ...

Israeli researchers have discovered a unique mechanism in marine bacteria that protects them from virus attacks, the Israel I ...

APSA-02 is under clinical development by Armata Pharmaceuticals and currently in Phase II for Bacteremia. According to GlobalData, Phase II drugs for Bacteremia have a 66% phase transition success ...

APPA-02 is under development for the treatment of multidrug-resistant chronic pulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients and non-CF bronchiectasis (NCFB). The drug ...